ELEKTA (NASDAQ:EKTAY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

According to Zacks, “Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company’s offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and Services. Elekta AB is headquartered in Stockholm, Sweden. “

ELEKTA (EKTAY) opened at 9.0501 on Monday. The stock has a market cap of $3.46 billion and a PE ratio of 226.2525. ELEKTA has a 1-year low of $7.85 and a 1-year high of $10.95.

ILLEGAL ACTIVITY NOTICE: “ELEKTA (EKTAY) Lifted to “Hold” at Zacks Investment Research” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/09/elekta-ektay-lifted-to-hold-at-zacks-investment-research.html.

Get a free copy of the Zacks research report on ELEKTA (EKTAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ELEKTA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA and related companies with MarketBeat.com's FREE daily email newsletter.